Thermo Fisher Scientific Inc., the world leader in serving science, is pleased to announce that that it is entering into a manufacturing agreement with Allecra Therapeutics GmbH for the commercialization of Cefepime/AAI101. Allecra Therapeutics is a clinical stage biopharmaceutical company established in 2013 dedicated to the development of novel treatments to combat multi-drug resistant bacterial infections. AAI101 is an extended spectrum novel beta-lactamase inhibitor. When combined with well-established beta-lactam antibiotics, it will target serious resistant hospital infections including complicated urinary tract infections, complicated intra-abdominal infections and hospital acquired pneumonia.
The dedicated facility within Thermo Fisher’s Swindon, UK site will provide manufacturing solutions for Allecra’s clinical needs plus provide a manufacturing runway to commercialization to allow this important product to reach patients in need of effective treatment. The Swindon site has a successful history of providing alternative business models such as dedicated and condominium suites to companies wishing to progress their products to market and provide a sustainable commercial supply.
For more information about Thermo Fisher’s site at Swindon, please click here.
SOURCE: Fisher Clinical Services